BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adasuve loxapine regulatory update

FDA accepted for review an NDA resubmission from Alexza for Adasuve to treat agitation in patients with schizophrenia or bipolar disorder. The agency designated the application as a Class...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >